NHD Global
Antimicrobial peptide research · Human cathelicidin
Scientific Product Dossier
LL-37 is the active peptide derived from human cathelicidin hCAP18 and is studied in innate immunity, microbial assays and host-cell signaling. An ocular-surface paper reported bacterial EC50 values of 1.3–3.6 µg/mL in vitro; it was not a patient treatment trial. FDA reports insufficient human safety information and nonclinical reproductive and tissue-specific tumor concerns.
Shared values below are consolidated from the current catalog record. They are not independent verification or lot results; the current product specification and lot COA control.
Product identity
Literature reference parameters
Identity safeguard Reference identifiers above describe the literature compound record. The supplied form, formula, molecular weight, purity and storage conditions must be verified against the product-specific specification and lot COA.
A target-to-pathway view grounded in the linked research records.
Reported research findings
Reported outcomes are paired with their experimental model and evidence boundary.
Reported EC50 values were 1.3–3.6 µg/mL across tested Pseudomonas and Staphylococcus strains.
Expression and direct-inactivation laboratory work; no patient administration.
Read the primary studyFDA identifies immunogenicity/characterization concerns plus nonclinical male-reproduction and protumorigenic findings.
These concerns require narrower public claims.
Read the primary studyCatalog options
Pack-level catalog data; lot-level controls remain document-specific.
Single-component peptide · 5 mg/vial nominal · 10-vial pack · supplied form and release limits controlled by lot specification.
Request by lot: CoA, HPLC purity and MS identity
Document availability is stated honestly and can vary by catalog variant or lot.
Analytical interpretation
Use the source-reviewed guide to separate chromatographic area purity, quantitative assay, LC-MS identity, composition and stability evidence before comparing variants or requesting a lot record.
Open the Quality & Documentation HubHPLC area ≠ assayA dominant peak does not establish target mass fraction.
Intact mass ≠ full sequenceIdentity strength depends on resolution and orthogonal evidence.
Counterions affect contentWater, salt form and solvents change the as-is composition.
Storage needs a data basisShipping practice is not the same as stability evidence.
Evidence map
Published studies and regulatory records, not customer testimonials or usage guidance.
Gordon YJ, et al. Current Eye Research. 2005. PMID 16020269.
View primary recordU.S. FDA current LL-37 summary.
View primary recordThird-party publications selected for direct relevance.
Gordon YJ, et al. Current Eye Research. 2005. PMID 16020269.
U.S. FDA. Current compounding safety-information page.
Concise answers for researchers comparing identity, evidence and catalog variants.
No. The cited ocular study measured expression and antimicrobial activity in laboratory assays.
No. Endogenous biology and exogenous exposure are different evidence questions.
Family-level identifiers organize the catalog, while the applicable product specification and lot-specific COA control the supplied form, identity and release results.
A lot-specific COA, product specification sheet and analytical method summary can be requested where applicable.
Store at -20 °C, protected from light and moisture. After reconstitution, aliquot and avoid repeated freeze-thaw cycles. Confirm the applicable storage statement on the product-specific specification and lot documentation.
Knowledge center
Owned educational content connected to this family.
A frequently cited LL-37 paper examined expression in human ocular-surface cells and antimicrobial activity in laboratory assays. It did not administer LL-37 as a…
Updated August 28, 2026
“LL-37” can refer to an endogenous human defense peptide, a synthetic assay reagent or an engineered biological delivery system. Results from one of those…
Updated August 28, 2026Knowledge tools
Move from this dossier into canonical evidence maps, verified status records, analytical interpretation and laboratory calculations.
Published-study results are tied to the linked records and kept separate from catalog-lot claims. Imported purity, storage and document-availability templates have been removed pending product- and lot-specific confirmation.
Technical procurement
Selected: 375 · 5 mg × 10 vials
Tell us what you need. Your enquiry will be routed to the appropriate contact for catalog numbers, availability and quotation details.
